Topic of the month.... Hereditary subcortical vascular dementia (CADASIL)
1. INDEX www.yassermetwally.com
INTRODUCTION
INTRODUCTION
Cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy (CADASIL) is the most
common hereditary subcortical vascular dementia. It is caused by the defective NOTCH3 gene, which encodes a
transmembrane receptor; over 170 different mutations are known. The main clinical features are migraine with aura
(often atypical or isolated), strokes, cognitive decline/dementia and psychiatric symptoms. Executive and organizing
cognitive functions are impaired first, memory is affected late. Typical MRI findings are T2 weighted hyperintensities
in temporopolar white matter and the capsula externa. Smooth muscle cells in small arteries throughout the body
degenerate and vessel walls become fibrotic. In the brain, this results in circulatory disturbances and lacunar infarcts,
mainly in cerebral white matter and deep gray matter. The exact pathogenesis is still open: a dominant-negative toxic
effect is suggested, possibly related to Notch3 misfolding. Diagnosis is reached either by identifying a pathogenic
NOTCH3 mutation or by electron microscopic demonstration of granular osmiophilic material in a (skin) biopsy. Only
symptomatic treatment is available at present.
Cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy (CADASIL) is the most
common hereditary vascular dementia. The disease is caused by more than 170 different stereotypic mutations in the
2. NOTCH3 gene encoding a 280 kDa transmembrane receptor [1, Suppl. table in 2]. The mutations lead to progressive
vascular smooth muscle cell (VSMC) degeneration, thickening and fibrosis of the vessel walls and accumulation of the
Notch3 extracellular domain (N3ECD) on the VSMCs. The four most common characteristic clinical symptoms of
CADASIL are migraine with aura, recurrent ischemic attacks, cognitive decline and psychiatric symptoms. Only
symptomatic therapy is available and thus, as a progressive disease, CADASIL leads to severe dementia and finally to
death, commonly within 20-25 years after symptoms have occurred.
Historical Annotation
The first CADASIL family was most likely reported by van Bogaert et al. in 1955 as a familial form of Binswanger's
disease.[3] This honor was long ascribed to Sourander and Wålinder, who in 1977 described an autosomally dominant
'hereditary multi-infarct dementia' with onset around 30-40 years of age.[4] However, this family was proven to have
another hereditary vascular dementia since no NOTCH3 mutation, or deposition of CADASIL pathognomonic
granular osmiophilic material (GOM) or N3ECD in arterial walls was detected.[5]
The linkage of the defective gene to chromosome 19 was established in 1993 by Tournier-Lasserve et al. who, at the
same time, gave the disease its present lengthy but descriptive name, cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy.[6] In 1996, the defective gene was reported to be NOTCH3 at chr19p13
[1] and the next year a detailed description of the stereotypic mutations (see below) in CADASIL was published.[7]
Epidemiology
Incidence & Prevalence
CADASIL has been reported worldwide in all ethnic groups. With better knowledge of its clinical picture and
improved diagnostic examinations, the number of CADASIL families is steadily increasing. The greatest number of
families have so far been identified among European Caucasians, while in the USA and Canada, the number of
reported cases has been surprisingly low considering the size of their populations, the high standard of neurology and
the high publishing activity in those countries. Exact incidence and prevalence figures are not available. In the UK,
prevalence has been estimated to be at least one per 100,000.[8] In the west of Scotland, the prevalence of CADASIL
with definite diagnosis is 1.98, and if patients with predicted diagnosis are included it is 4.14 per 100,000.[9] These
figures are identical to those in Finland where the prevalence of molecular genetically verified patients is
approximately two, and when based on family history it is four per 100,000 [Own Unpublished Observation]. One of
nine (11%) patients aged 50 years or below with lacunar infarcts and leukoaraiosis suffered from CADASIL, whereas
among patients aged 65 years and below the frequency was one of 48 patients (2%; with estimated 90% sensitivity of
the genetic analysis, based on screening for mutations in exons 3, 4, 5 and 6 by PCR followed by analysis for single-
stranded conformational polymorphism).[10,11] However, definite prevalence figures must await analyses on large
enough populations.
Clinical Features
Females and males are equally affected. The four cardinal manifestations of CADASIL are:
1. Migraine with aura (aura being often atypical or isolated)
2. Ischemic attacks (transient or strokes)
3. Cognitive decline and dementia
4. Psychiatric symptoms
The age of onset of CADASIL varies greatly, which also depends on thecriterion used for the onset of the disease. Since
migraine (see below) is as common as an independent disease, the age of onset is usually given on the basis of the first
ischemic attack. However, it is difficult to distinguish between a transient ischemic attack and isolated migraineous
aura (without headache), which may be very severe and long lasting in CADASIL. The age at the first ever stroke
varies from approximately 25 to 70 years with a reported peak around 40-50 years of age and with great variation
even within the same family,[12-14] and even between monozygotic twins.[15] Thus, in general, the site of NOTCH3
mutation does not seem to influence the onset and course of the disease,[16] but a lower age of onset has been reported
3. to associate with mutations p.Cys174>Tyr [17] and p.Cys455>Arg .[18] CADASIL is usually slowly progressive and it
leads to death within a mean of 23 years (range: 3 to 43 years).[13] A few late-onset patients survived to old age, the
eldest known CADASIL patient being a Finnish female, who died at the age of 96 years after a 28-year-long course [S
Tuisku, Pers. Comm].
Migraine
Recurrent migraineous headache is a common symptom, it occurs in up to 60% of CADASIL patients and in 22-40%
of the patients associated with aura. Migraine attacks may begin even before the age of 10 years, but more commonly
during the third or fourth decade.[12,13,19] The aura is commonly a visual or sensory disturbance, often atypical and
long lasting and exceptionally severe, causing even hemiplegia, in which case hemiplegic migraine is a differential
diagnostic possibility.[20] Because migraine is so common it may be overlooked as a manifestation of CADASIL. The
severity of migraine may become milder, less frequent or even cease after the first ischemic attack.[13] On the other
hand, in females, the first migraneous attack often occurs or the attacks are aggravated in late pregnancy or during
puerperium, often associated with other neurological symptoms.[21]
Ischemic Attacks
The most common manifestation (85%) in symptomatic CADASIL patients is recurrent ischemic insults of variable
severity.[12-14] The first insults are often transient ischemic attacks with rapid recovery, which are difficult to
distinguish from severe migraineous aura or episodes of hemiplegic migraine unless ischemia can be verified by MRI.
Most commonly the strokes are typical lacunar syndromes, such as pure motor or pure sensory strokes, dysarthria
clumsy hand syndrome, expressive dysphasia or visual field defects, whereas major strokes due to large infarcts in the
territories of the main cerebral arteries are very rare.[22,23] With progression, difficulties in locomotion and
movement disorders (including vascular Parkinsonism due to infarcts in basal ganglia), pseudobulbar paresis and
urinary incontinence may appear. Finally, patients lose their ambulation. Strokes may also be caused by infarcts in the
brain stem and rarely in the spinal cord. In 5-20% of patients, subcortical dementia develops without diagnosed
clinical strokes[24, 25, Own Unpublished Data] , although silent infarcts may be detected in MRI in the white matter
(WM) or basal ganglia, where the symptomatic infarcts are also located (Figure 1).
Figure 1. The lacunar infarcts (arrow) are
located either in the cerebral white matter or in
the basal ganglia, whereas the cortex is well
preserved. Reproduced with permission from
[14].
Major parenchymal brain hemorrhages (PBHs) are relatively uncommon in CADASIL (although in a small Korean
cohort of 20 patients as many as 25% were struck by a PBH[26] ), and antithrombotic therapy and hypertension
appear to be contributory factors.[26-28] Small microbleeds (see below section, Imaging) are considered to indicate an
increased risk of PBH, athough these themselves are most often asymptomatic.
Cognitive Decline & Dementia
4. When the tissue damage is of sufficient severity, cognitive decline ensues affecting predominantly frontal lobe
functions in particular causing executive dysfunctions. The decline is detectable in neuropsychological tests as early as
the prestroke phase of the disease.[29,30] Patients have impaired executive and organizing functions, general mental
and psychomotor slowing, poor concentration and narrowing of the field of interest, whereas they perform relatively
well in the routine Mini-Mental State Examination. Later on, memory and other cognitive functions are affected,
leading to a subcortical type of vascular dementia.[29,31,32] Cognitive decline becomes clinically manifest between 40
and 70 years of age and approximately 80% of the CADASIL patients have become demented by 65 years of age.[13]
The MRI load of lacunar infarcts is independently associated with the severity of cognitive dysfunction, whereas WM
hyperintensity lesion load and microbleeds do not associate after correcting for age in cross-sectional studies.[33,34]
Psychiatric Manifestations
Mood disturbances are CADASIL patients' most common psychiatric disorder (present in ~20-30%).[12,13,28] As
expected, depression is the most common disturbance, especially in those patients who have confronted the disease in
their family and have a preserved insight of their disease. Manic episodes are rare. Psychotic disorders were common
in a large French family, wherefore they were considerd to represent a variant phenotype of CADASIL.[35] A single
CADASIL patient with schizophrenia has been reported.[36] In addition, paranoia, agitation and aggression,
dysthymia and emotional lability have been described.[37,38] However, their relationship to CADASIL has not been
established.
Additional Clinical Findings
Routine clinical laboratory examinations are nearly always noncontributory.
Epileptic seizures occur in approximately 7-10% of the patients. They occur most often at the later stages of the
disease, but only rarely does CADASIL present with epileptic seizures.[13,16,25,39] Nonconvulsive status epilepticus
with focal neurological deficit has also been reported, which may be misinterpreted as an ischemic stroke.[40] An
acute reversible encephalopathy ('CADASIL coma': confusion, fever, headache and fits) that poses a risk of
misdiagnosis of encephalitis has been reported to be an underdiagnosed presentation of CADASIL.[41] Sensory motor
neuropathy has been detected both electrophysiologically and by nerve biopsy.[42] Bothersome urge incontinence has
been observed in many CADASIL patients [Kalimo H, Unpublished Results].
CADASIL is a generalized arteriopathy even though the symptoms are almost exclusively neurological and the
ischemic lesions are in the CNS. Thus, myocardial ischemia could be expected to be common in CADASIL patients.
The reports are contradictory. Lesnik Oberstein et al. found that almost 25% (10 out of 41) of NOTCH3 mutation
carriers had evidence of myocardial infarction.[43] On the contrary, Cumurciuc et al. found no ECG evidence for
myocardial infarction or ischemia, conduction disturbances or arrhythmias in CADASIL patients compared with
healthy controls.[44] In the latest study, Rufa et al. presented data consistent with autonomic nervous derangement.
They suggested that CADASIL patients may be at risk for life-threatening arrhythmias, which might be one
explanation for their higher risk of sudden unexpected death.[45]
In a recent meta-analysis, CADASIL patients were reported to also suffer from neuromuscular symptoms, weakness,
wasting, reduced/exaggerated tendon reflexes, abnormal nerve conduction and electromyography. Their muscle
biopsies had revealed alterations indicating mitochondrial pathology: ragged red muscle fibers, reduced COX
staining, decreased complex I respiratory chain activity, abnormally structured mitochondria or mitochondrial DNA
(mtDNA) mutations.[46]
In conclusion, most of these additional clinical findings are not specific and, thus, not of diagnostic significance in
CADASIL, but should be considered in the care of CADASIL patients.[47]
Risk Factors
The occurrence of cardiovascular risk factors is similar to that of the general population. Hypertension is uncommon,
which differs from other cerebrovascular diseases.[12,16,25] Smoking may increase the risk for stroke in CADASIL
patients. In some, but not all, patient cohorts hypercholesterolemia has been common. CADASIL patients may be
more susceptible to their harmful effects because of lesser cardiovascular reserve.[48-50]
Imaging
5. Hyperintensities on T2-weighted (T2w) MRI in temporopolar WM, periventricular cerebral WM (Figures 2A & 2B)
and capsula externa are characteristic early findings in CADASIL,[51] and at advanced stages virtually all cerebral
WM is involved (Figure 2C). These WM findings are comparable with the MRI diagnosis of leukoaraiosis and may be
deceptively reminiscent of multiple sclerosis. Diffusion tensor MRI reveals a marked increase in water diffusivity, and
the diffusion can occur more freely in any direction indicating loss of anisotropy.[52] This reflects microstructural
change with enlargement of the extracellular space due to vasogenic edema, possibly associated with myelin and
axonal damage, an interpretation well compatible with the microscopic picture in CADASIL WM. These alterations
are also detectable in the normal appearing WM outside the T2w hyperintensities indicating an incipient
microstructural abnormality.
Figure 2. MRI findings in cerebral autosomal dominant arteriopathy with subcortical infarct and
leukoencephalopathy.
(A) Hyperintensities in anterior temporal lobes in T2-weighted (T2w) MRI are characteristic early alterations in
CADASIL. A 29-year-old female at the time of her first transient ischemic attack. (B) Another typical T2w MRI
alteration is punctiform periventricular hyperintensities. A subjectively healthy 40-year-old male. (C) Advanced stage
of dementia with extensive white matter hyperintensities. A 54-year-old male. (D and E) In fluid-attenuated inversion
recovery MRI, lacunar infarcts are visible both in the white matter and in basal ganglia (arrows). (D) A 57-year-old
female. (E) A 54-year-old male. Asterisk in D denotes frontal horn of the lateral ventricle.
In symptomatic CADASIL patients who have experienced strokes (in ~10-15% of cases infarcts are silent), a variable
number of small (lacunar) infarcts can be identified in T1w and fluid attenuation inversion recovery (FLAIR) MRI
(Figures 2D & 2E)and computerized tomography (CT). The infarcts are most commonly located in cerebral WM and
6. deep gray matter (GM = basal ganglia), whereas the cerebral cortex remains remarkably intact (Figure 1).
Small hypointensities in T2w gradient echo MR corresponding to microbleeds are detectable in 31-69% of the
CADASIL patients. Microbleeds show a preference for cortical-subcortical regions, subcortical WM, thalamus and
brainstem. Their frequency increases with patients' age and volume of T2w lesions.[53,54] They are more common in
patients with antiaggregant therapy.[53] The hyperintensities are due to perivascular accumulations of hemosiderin-
containing macrophages, indicating focal extravasation of red blood cells. Microbleeds also occur in other small-vessel
diseases of the CNS, such as arteriolosclerosis and amyloid angiopathy. The significance of microbleeds for the
pathogenesis of CADASIL is still uncertain, since they are clinically silent and most common in the relatively spared
cerebral cortex, 82% being outside the T2w hyperintensities or ischemic lesions. Thus, microbleeds were considered to
be largely an independent manifestation of the underlying angiopathy.[54] Neither does the number of microbleeds
associate with the severity of cognitive dysfunction.[33] Nevertheless, they are considered to predict an increased risk
of PBH.[53,54]
Conventional cerebral angiography is non-contributory, and it appears to carry a considerably increased risk of
complications, most often hemorrhages.[55]
Circulatory Disturbances in CADASIL
Reduced cerebral blood flow (CBF) has been demonstrated in CADASIL with several functional imaging methods,
such as single photon emission CT (SPECT),[24] PET,[56,57] MRI bolus tracking method[58,59] and Doppler
sonography.[58] PET examination has shown that the reduction of CBF in the WM already appears at
presymptomatic stage and becomes more clear beyond 30 years of age, at which age first strokes may also appear
(Figures 3A & 3B). In the cerebral cortex, CBF is not reduced until later symptomatic stages, and even then only to a
lesser degree in concordance with the paucity of cortical infarctions. In a presymptomatic subject, the oxygen
extraction fraction (OEF) was increased, indicating that the brain tissue could compensate for the decreased CBF by
increasing the OEF. On the other hand, not until later stages parallel to the development of dementia were cerebral
metabolic rate of oxygen (CMRO2)[56] and glucose consumption (CMRgluc)[57] reduced, indicating that the decrease
in CBF is due to the arteriopathy not secondary to tissue loss. With the MRI bolus tracking method, decreased CBF
and cerebral blood volume (CBV)[58,59] were recorded within areas of T2w hyperintensities in the WM, where
reductions were more severe in demented than in nondemented patients. A trend of reduced CBV was already
observed within the normal-appearing WM.[58] Furthermore, the hemodynamic reserve is reduced in CADASIL
patients, since the acetazolamide-induced increase in CBF and CBV was lower in T2w hyperintense areas.[58]
Prolonged arteriovenous cerebral transit time in both disabled and nondisabled CADASIL patients has been
demonstrated by Doppler sonography.[60]
Figure 3. Positron emission tomography shows
decreased cerebral blood flow in a 34-year-old
male CADASIL patient (left) with strokes
compared with a 31-year-old male control
subject (right).
Since CADASIL is a generalized arteriopathy, derangement of vasoregulation in the systemic vasculature is not
surprising. Stenborg et al. showed impaired endothelium-dependent vasodilation in resistance arteries in the forearm
of CADASIL patients, but not in a large conduit artery, a. brachialis, which resulted in reductions in both basal and
stimulated blood flow.[61] Similarly, transgenic mice expressing mutant NOTCH3 showed early impairment in flow-
mediated vasodilatation in resistance vessels, although extrapolation of mouse results to humans requires caution (see
below section, Animal models).[62]
7. Pathology
Biopsy Findings
Although the symptoms of CADASIL are almost exclusively neurological, blood vessels (mainly medium sized and
small arteries) throughout the body are affected (Figures 4-6). A pathognomonic feature of CADASIL is the presence
of GOM (Figures 4, 5A & 5B) detectable with electron microscope (EM) on the VSMCs in the walls of the affected
vessels. GOM was originally demonstrated by Baudrimont et al. and Ruchoux et al. [63,64] and it has not been
detected in any other disease. GOM is located either in indentations on the degenerating VSMCs or free between these
cells, the basal lamina of which is usually irregularly thickened (Figures 4, 5A & 5B). Both accumulation of GOM and
degeneration of VSMCs are detectable already before 20 years of age (Figure 5B).[65,66] The exact composition of
GOM is not yet clear, but on the basis of immunoelectron microscopy N3ECD has been suggested to be a major
component of GOM.[67] By light microscopic immunohistochemistry with antibodies against N3ECD, introduced by
Joutel et al. , the vessel walls stain diffusely positively (Figure 6A).[68] With confocal microscopy N3ECD
immunoreactivity appears as dot-like accumulations on the surface of VSMCs, in concordance with the appearance of
GOM deposits in EM (Figure 6B).
Figure 4. Electron micrograph of a dermal artery from a patient at an early stage of the disease. A 28-year old male
with p.Arg133Cys mutation. Note the widened subendothelial spaces (asterisks) and irregular smooth muscle cells (M)
on which there are three deposits of granular osmiophilic material (arrows). E: Endothelial cell.
8. Figure 5. Electron micrograph showing presence of granular osmiophilic material. (A) In a 48-year-old patient who
had already suffered from a couple of strokes relatively abundant granular osmiophilic material (GOM; asterisks) is
present in the indentations of two vascular smooth muscle cells. (B) A small amount of GOM is already present in a
19-year-old patient carrying the p.Arg133Cys mutation. GOM is located in a deep invagination, which might be
difficult to detect by immunohistochemistry.
Figure 6. ince CADASIL is a generalized
arteriopathy, its characteristic
pathological alterations are also visible in
skin biopsy. (A) A 57-year-old female with
p.Arg133Cys mutation. N3ECD is present
in the wall of the small dermal arteries
(asterisks). (B) A 62-year-old male with
p.Tyr1069Cys mutation. Confocal
microscopy demonstrates N3ECD
immunoreactivity as small dots along the
vessel wall, a finding compatible with the
deposits of GOM (see Figures 4 & 5).
Autopsy Findings
Macroscopy. In accordance with the imaging findings, there are multiple small (lacunar) infarcts in the WM and/or
deep GM, whereas the cerebral cortex is markedly well preserved (Figure 1). Lacunar infarcts are also relatively
common in the brain stem. Even though the microbleeds are fairly common (see above section, Imaging), parenchymal
brain hemorrhages are relatively uncommon. These have most often occurred in patients treated with anticoagulants
or antiaggregants, or subjected to arteriography.
Histopathology. Histological stainings reveal markedly thickened small arteries in WM with accumulation of granular
material in the degenerating tunica media. This material is basophilic in hematoxylin and eosin and red in periodic
acid-Schiff stainings (Figures 7A-7C). Decreased immunopositivity for a-smooth muscle actin reveals degeneration of
9. the VSMCs (Figure 7D). The accumulation of N3ECD may be verified by immunohistochemical staining (Figure 7E).
It is the accumulation of extracellular matrix proteins, including various types of collagens and laminin outside the
degenerating VSMCs, that causes the thickening of the vessel walls (Figure 7F). On the basis of the stainings described
above, CADASIL can be distinguished from the two other arteriopathies with thickened walls: in arteriolosclerosis
(Binswanger disease) and cerebral amyloid angiopathy, the walls are homogeneously stained, either collagen or similar
to amyloid.
Figure 7. Hstopathological findings in CADASIL patients' brain. A) A small arteriole from the cerebral white matter
of a control person. (B) The wall of a corresponding arteriole from a CADASIL patient is markedly thickened and the
lumen stenosed. Note the basophilic granular material in the thick media and adventitia. (C) The granular material in
B is PAS-positive. (D) The degeneration of vascular smooth muscle cells (VSMCs) appears either as almost complete
loss of a-SMA-stainable VSMCs (left arteriole) or their irregular pattern (right arteriole). (E) N3ECD accumulates in
the tunica media of affected arterioles. (F) The degenerated VSMCs have been replaced by abundant collagen I. -
SMA: a-smooth muscle actin; N3ECD: Notch3 extracellular domain; PAS: Periodic acid-Schiff.
The marked thickening of the walls of small penetrating arteries in cerebral WM is reflected numerically in the highly
significant increase of sclerotic index (SI = 1-internal diameter/external diameter; 0.75 vs 0.35-0.40 in controls).[69]
Within WM, the small arterioles (<130 µm external diameter) are most severely affected, and at the same time they
become stenosed with significantly smaller mean internal (luminal) diameters (Figures 8 & 9).[69] Finally, these
arterioles must become severely enough obliterated or thrombosed to give rise to lacunar infarcts in cerebral WM
(Figures 1 & 8). In the cerebral cortex, the small arteries and arterioles are also thickened (SI: 0.56 vs 0.48 in controls)
and their lumina somewhat narrowed (Figure 9), but to a considerably lesser extent than in WM, explaining the
absence of cortical infarcts.[69] Corresponding to the presence of the microbleeds in imaging, perivascular deposits of
hemosiderin may be found.[54] These are located predominantly in GM, which may simply depend on the fact that the
10. walls of arterioles in GM are less thickened than in WM and therefore more fragile[69] and prone to extravasation.
Figure 8. Hogressive fibrosis of the affected arterioles in cerebral white
matter may lead to complete obliteration of the affected arteriole. Note
the loose texture of the surrounding infarcted tissue.
Figure 9. Mean diameters of arteriolar (0-
50 µm) lumina demonstrate the stenosis
occurring in CADASIL patients, most
marked in the cerebral white matter and at
more advanced stage. Horizontal lines
above the columns indicate the two groups
compared. The asterisks above the lines
indicate statistical significance. The
numbers of arterioles measured are given
in brackets under each column.
CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy; GM: Grey
matter; LN: Lentiform nucleus; n: Numbers of CADASIL patients (elderly with pArg133Cys mutation, mean age:
63.4 ± 2.9 years, range 60-68 years, young with pCys174Arg mutation, age 32 years); n1: Numbers of controls for GM
and WM ; n2: Numbers of LN controls; WM: White matter.
Interestingly, the small arteries in the deep gray matter of basal ganglia (nucleus lentiformis ) - the other region in the
brain, where lacunar infarcts occur in CADASIL - behave differently. These vessels are not stenosed (Figure 9) as in
WM even though their walls are thickened, suggesting a different, most probably hemodynamic, pathogenesis for the
lacunar infarcts in the basal ganglia.[70]
These findings suggest that there is a fundamental difference between the cortical and WM arteries. The response of
VSMCs to the gene defect appear to be markedly different, which is also reflected in the magnitude of the fibrotic
reaction. Similarly, it was recently shown in NOTCH3 -knockout mice that the contractile activity of VSMCs in the
aorta is different from that of cerebral arteries.[71]
Since NOTCH3 is mainly or exclusively expressed in VSMCs, the main interest has been targeted at these cells and
their degeneration. Ruchoux and Maurage have performed the most detailed structural analysis of endothelium in
skin and skeletal muscle biopsies.[72] They found attenuation of endothelial cells and increased density of their
11. cytoplasm with accumulation of microfilament bundles. Widening of subendothelial space has also been observed
(Figure 4). Interaction between endothelial and vascular smooth muscle cells has been identified as a central process in
the regulation of vascular formation, stabilization, remodeling and function.[73] During development, expression of
Notch3 signaling appears to be necessary for correct specification of arterial and venous characteristics of the VSMCs
in the blood vessel walls.[74] Thus, the pathological findings in CADASIL patients' endothelium may reflect functional
disturbances: we have shown impaired endothelium-dependent vasodilation in CADASIL patients' forearm resistance
arteries,[61] and in addition, other studies have suggested endothelial dysfunction.[75]
Genetics
Linkage of the CADASIL gene to chromosome 19 was discovered in 1993;[6] 3 years later the defective gene was
identified as NOTCH3 in 19p13.1-13.2.[1] A great majority (well over 95%) of CADASIL cases are due to missense
point mutations in N3ECD in exons 2-23 (Figure 10). Over 170 different point mutations have been identified.[2]
Virtually all point mutations result in an amino acid substitution involving cysteine, either a replacement of a wild-
type cysteine with another amino acid or vice versa, resulting in an uneven number of cysteines (normal number six)
in the affected EGF-like repeat in N3ECD. In addition to the point mutations, eight different deletions have been
described. These result in a loss of either one or three cysteine residues and, thus, similarly in an uneven number of
cysteines, which is also the consequence of one mutation with insertion of an extra cysteine [Suppl. table in 2].
Figure 10. Notch signaling. Notch3 is constitutively cleaved by furin (S1) and the bipartite molecule is inserted to the
plasma membrane. The Notch3 extracellular domain (N3ECD) consists of 34 EGF-like repeats, followed by three
notch/lin-12 repeats, a transmembrane domain and an NICD, which contains five ankyrin repeats. The binding site of
the ligand (in human delta or jagged) is at EGF repeats 10-11. Upon binding, N3ECD is cleaved at 12 amino acids
external to the intramembranous domain (S2). Thereafter occurs the intramembranous S3 cleavage and NICD enters
the nucleus to release the repressor molecules CoR and HDAc, which bind to a transcription regulator of the CSL
family, RBP-Jk and activate transcription. CADASIL mutations are in EGF repeats 1-32 (exons 2-23) between the
asterisks. The non-CADASIL Notch3 mutation is located in exon 25 (triangle). TACE: TNF-a-converting enzyme;
CoRHAc and MAML1: Components of an activation complex; NICD: Notch3 intracellular domain.
There is a marked clustering of mutations at the N-terminus of the NOTCH gene: approximately 62% of the reported
mutations are located within exons 3, 4, 5 and 8 encoding for the first five EGF repeats [Suppl. table in 2, 6]. In two
families, de novo mutations causing p.Arg182>Cys[76] or p.Cys128>Gly[77] substitutions have been verified. One
CADASIL patient has been diagnosed to be homozygous for the c.397C>T mutation, which causes a relatively
common p.Arg133>Cys substitution.[65] The homozygous patient's phenotype was still within the normal spectrum
although relatively severe. Since this patient's heterozygous son appears to have a similar phenotype CADASIL
appears to follow the classic definition of dominant pattern of inheritance, in other words, the phenotypes of the
heterozygous and homozygous patients are indistinguishable. Finally, seven CADASIL patients/families with a
noncysteine mutation have been reported.[2,78,79] Interestingly, a noncysteine mutation in exon 25 (p.Leu1515>Pro;
Figure 10) of NOTCH3 was recently shown to cause a non-CADASIL small-vessel disease without accumulation of
12. N3ECD or GOM on the VSMCs. This mutation causes constitutively active Notch3 signaling exceeding the wild-type
activity approximately tenfold.[80]
Notch3 Biochemistry
Notch3 is a member of the Notch family, which in mammals has four members (Notch1-4). Notch signaling is very
important during development and, accordingly, Notch molecules are highly conserved during evolution. Orthologous
genes with a high degree of homology exist from nematodes to man.[81] The Notch pathway is important, for example
in stem cell renewal, proliferation, determination of cell fate and differentiation and apoptosis during organogeneses,
including vasculogenesis.[81-84]
Structure
The human NOTCH3 gene has 33 exons and encodes for a 2321 amino acid Notch3 receptor with a single
transmembrane domain (Figure 10).[1,85] The N-terminal extracellular part of the molecule contains 34 EGF-like
repeats followed by three notch/lin-12 repeats. The recognition site of the ligand is at EGF repeats 10 and 11. Each
EGF repeat contains six cysteines, which form sulphur bridges when the protein domain is folded. The intracellular
domain on the Notch3 contains RBP-J?-associated molecule region in the juxtramembrane part, five ankyrin repeats
and a C-terminal PEST-motif.
Ligands
Delta-like family (DLL1, 3 and 4) and Serrate family Jagged (JAG1 and JAG2) are the ligands for Notch receptors.
[86-88] The molecular structure of Delta and Jagged is very similar to that of Notch. They are transmembrane
proteins with large extracellular domains containing several EGF-repeats. VSMCs express both the ligand and the
receptor on the cell surface but the signal transduction seems to occur only between neighboring cells.[89,90]
Signaling
The molecular mechanism of receptor maturation, ligand binding and transcription activation are presumed to be
similar for all Notch receptors. Notch receptors are cleaved three times during maturation and signaling (Figure 10).
First, Notch is translated as a single polypeptide chain and cleaved by a furin-like convertase in the Golgi (S1
cleavage). The two cleavage products are held together by metal ions (Ca2+ ) generating a bipartite molecule that is
inserted into the plasma membrane.[91] The ligand binding induces the second proteolytic cleavage by TNF-a-
converting enzyme (TACE, ADAM-17) at the site S2 located 12 amino acids external to the intramembranous domain.
[92] N3ECD is released and transendocytosed with the ligand to the ligand-expressing cell (Figure 11, item D).[89,90]
Finally, the Notch transmembrane-intracellular domain is cleaved (S3) within the plasma membrane by ?-secretase,
[93] which is a complex of presenilin1, nicastrin, Aph-1 and Pen-2.[94] This same enzyme cleaves ß-amyloid precursor
protein, participating in the production of the pathogenic ß-amyloid peptide in Alzheimer's disease. S3-cleavage
releases the Notch3 intracellular domain (NICD), which then enters the nucleus and binds a DNA-binding CSL family
of transcriptional regulators (CBF1, Suppressor of Hairless and Lag-1, and CBF1/RBP-J? in mammals).[81,82] The
NICD replaces co-repressors from the CSL and forms a transcription-activating complex in which it further recruits
co-activator proteins (Figure 10). Exactly how Notch3 regulates the development and differentiation of VSMCs is
unknown. Neither has the exact function of Notch3 been clarified in adult animals, in which Notch3 appears to be
exclusively expressed in VSMCs,[95,96] which may have different molecular phenotypic and physiological
characteristics in different vascular beds.[69,71] Interestingly, in a recent article the ischemic lesions induced by
occlusion of the proximal middle cerebral artery by a filament were reported to be approximately two-times larger in
homozygous NOTCH3 -knockout mice than in wild-type or heterozygous NOTCH3 +/- mice. This indicates a striking
susceptibility to ischemic stroke, which was normalized if wild-type human NOTCH3 was conditionally expressed in
the NOTCH3 -/- mice. Thus, it was suggested that Notch3 defines a key determinant of stroke burden through
regulation of VSMC function.[71]
13. Figure 11. Possible (proven and hypothetical) pathogenic effects in association with mutated (misfolded?) Notch3.
NICD: Notch3 intracellular domain. Notch Signaling is Regulated by Endocytosis
In experiments using Drosophila or mouse skeletal muscle myoblasts, it has been shown that the ligand-N3ECD
complex is internalized to the signal-donor cell.[89,90] After the first interaction between Notch and ligand, both the
signal-donor and signal-receiving cell will continue the signal activation cascade by clustering new receptors on the
signal-receiving cell and new/recycled ligands on the signal-donor cell surface.[97,98] It is not definitely clarified
whether the ligand is first internalized to enter a special endocytic pathway for conversion from inactive into active
form to be then recycled onto the signal-donor cell in the activated form, or whether initial interaction between the
ligand and N3ECD is needed for the ligand recycling cascade to begin.[97,98] As for the role of endocytosis in the
pathogenesis of CADASIL, see the below section: Internalization of the N3ECD.
Pathogenesis
Molecular Pathogenesis
The exact molecular pathogenetic mechanism causing CADASIL is unknown. It has been suggested that proteolytic
processing and targeting of Notch3 receptor, signaling or ligand binding and internalization of the cleaved N3ECD
could be affected.[28,95,99]
Notch3 Processing & Targeting. Although alternative proteolytic processing has been suggested to be a possible cause
of CADASIL, no definite proof has been presented.[100,101] It seems clear that in CADASIL the mutated Notch3
14. receptor molecules are targeted to the cell surface and that S1 cleavage has occurred. Whether S2 cleavage has to
precede S3 cleavage is unknown, but since the Notch3 canonical signaling is functional, the S3 cleavage has most
probably occurred (Figure 10).
Signaling & Ligand Binding. Some CADASIL cases are caused by mutations that lead to the loss of ligand binding on
Notch3 (Figure 11). The clinical outcome is, however, identical to those with the mutation outside of the ligand-binding
site. Thus, it would be difficult to explain that loss of function would be the cause of CADASIL. Several pieces of
evidence oppose the loss of function of Notch3, for example, Joutel et al. [100] and Peters et al. [101] demonstrated that
only specific mutations located in the ligand-binding site in EGF repeats 10-11 (p.Cys428>Ser and p.Cys455>Arg)
exhibited a significant reduction of transcriptional activity via the RBP/Jk pathway (Figures 10 & 11) while all other
mutations tested were shown to have close to normal signaling activity. Furthermore, Notch3-deficient mice do not
develop CADASIL pathognomonic GOM deposits.[102] Physiological levels of wild-type human Notch3 and the
mutant pArg90>Cys human Notch3 rescued the arterial defects of NOTCH3 -/- mice to similar degrees and exhibit
normal levels of Notch3/RBP-Jk activity in brain arteries.[103] And finally, the similar phenotype in the homozygous
and heterozygous CADASIL patients also favors a mechanism other than loss of receptor function[65] as does the lack
of truncating mutations in CADASIL.[101]
Evidence against gain of Notch3 receptor function is based on the same experiments as for loss of function, in
particular, cells expressing mutated Notch3 show normal signaling activity.[100,101] However, it was pointed out that
the experiments were limited to the major Notch signaling pathway, and CADASIL mutations may affect other Notch
signaling pathways that have been shown to exist.[101,104-106] Gain of Notch3 function has been reported in a patient
with cerebral small-vessel disease lacking GOM deposits and Notch3 accumulation. This mutation is located in the
juxtamembranous region of Notch3, which constitutes the heterodimerization domain (Figure 10). The mutation
destabilizes the metal ion bridge leading to a ligand-independent, constitutively-active receptor.[80] Thus, it seems that
gain of function leads to a cerebral small-vessel disease different from CADASIL.
Internalization of the N3ECD. It has been shown that in CADASIL, the accumulated Notch3 contains only its ECD.
[95] This accumulation of N3ECD on the surface of VSMCs has been considered pivotal in CADASIL, although the
reason for the accumulation has remained unclear. Joutel et al. found almost identical amounts of N3ECD in
CADASIL patients regardless of whether their mutations were located at or outside the binding site, indicating that
Jagged1 binding is not a prerequisite for N3ECD accumulation.[100] Normally, N3ECD would be transendocytosed
with the ligand to the signal-donor cell (Figure 11).[89] The ligand ECD bound to the Notch ECD as a trans-complex is
assumed to place mechanical strain on the Notch3 protein, which exposes the cleavage site to be targeted by TACE for
S2 cleavage.[98] Inefficient ligand binding could lead to weaker mechanical strain, and inhibition of S2 cleavage and
subseqent internalization of N3ECD.[97]
Misfolding. Since practically all the CADASIL mutations lead to an uneven number of cysteine residues in the
mutated EGF repeat, normal formation of sulphur bridges does not occur and the Notch3 receptor 3D structure is
altered. This may cause secondary modifications in Notch3 processing, such as impaired proteolytic S1 cleavage by
furin or O -linked glycosylation by Fringe and aberrant dimerization of Notch3, which could all contribute to the
accumulation of N3ECD on the VSMC surface.[107] Usually a cell can determine the ability of a protein to form
disulphide bridges at the endoplasmic reticulum (ER). If for any reason the protein cannot form the predefined
number of disulphur bridges, the protein is directed to ubiquitylation and subsequent proteosomal degradation.[108]
The mutated Notch3 seems to escape this degradation and is transported to the cell surface as a misfolded protein.
[95,101,107-109] CADASIL cells are oxidatively stressed and have upregulated proteasomal degradation, which are
typical signs for impaired sulphur bridge formation, misfolding of proteins and ER quality control failure.[110] These
problems in the protein folding and degradation can lead to degeneration of VSMCs. Misfolding of the receptor does
not seem to influence the ligand binding or the CSL/RBP-Jk-signaling if the mutation is not on the ligand-binding site.
[100,101] Thus, inactivation of the canonical Notch3 signaling is not necessary for CADASIL. The only feature
common to all CADASIL mutations is the accumulation of N3ECD on the VSMC surface. In the transgenic mice
expressing mutated (p.Arg90>Cys) human Notch3, Monet et al. reported normal Notch3 function in vivo (mice) with
no dominant-negative interfering activity despite accumulation of mutated N3ECD on the VSMCs as in CADASIL.
[103] Thus, they suggested that the mutated Notch3 does not have such a dominant negative 'sop up' effect as
suggested by Spinner (Figure 11).[111] Whether the accumulation in mice is comparable to that in the decades-long
human CADASIL is an open question. In humans, N3ECD accumulation may become excessive and pathogenic with
age and gradually lead to disturbances in the cell-cell and cell-extracellular matrix interactions, including ligand
binding.[111] But all in all, we do not yet know whether the accumulated N3ECD is really pathogenic or is just a
marker for ongoing cellular damage.
15. Alternative Signaling Pathways. In vitro and in injured rat carotid artery it was demonstrated that activation of
Notch3 signaling was associated with increased expression of c-FLIP, an inhibitor of Fas ligand-induced apoptosis.
[112] However, the pathway from activation of Notch3 to enhanced survival signals is still open.[112-114]
CADASIL leads to arteriopathy causing blood flow disturbances, especially in the resistant arteries.[61,62] The key
proteins in VSMCs contraction are myosin and actin. SMC-specific smooth muscle cell a-actin is a direct target of the
canonical Notch3 pathway.[115] The expression of constitutively active Notch3dE in cultured VSMCs resulted in
increased actin stress fibers and steady-state levels of polymerized actin.[74] In authentic human CADASIL cells,
several proteins interacting with the actin cytoskeleton were differentially expressed and the ability of these cells to
contract was impaired.[110] These studies suggest that Notch3 is involved in the regulation of the actin cytoskeleton
and may act as a sensor or a signal transmitter that enables VSMC to respond to mechanical stretching of the vessel
wall.
In a recent article, Notch signaling was linked to PDGF signaling, another key determinant of VSMC biology.[104] It
was demonstrated that PDGF-receptor ß is a novel immediate Notch target gene. PDGF signaling is important in
vascular development and for homeostasis of blood vessels. Four different ligands (A-D) bind to PDGF-receptor
tyrosine kinases (PDGFR-a and -ß), which activate several intracellular signaling cascades. In particular, PDGF-
ß/PDGFR-ß signaling has been shown to be important, since defects in this pathway cause vascular abnormalities such
as hemorrhage, microaneurysms and VSMC hypoplasia.[116] PDGF released in vascular injury leads to
downregulation of VSMC marker genes, increased VSMC proliferation and vascular remodeling.[117] PDGF
stimulation inhibits Notch3 expression and signaling and increases Jagged1 expression.[116-119] PDGFR-ß was
recently demonstrated to be an immediate downstream target gene of Notch3 activation.[104] Notch3-deficient adult
mice exhibit vascular abnormalities and have reduced PDGFR-ß expression in arteries of the tail lateral bundle.
Furthermore, Notch-ligand stimulation of VSMCs resulted in significantly reduced induction of PDGFR-ß expression
in authentic human CADASIL cells (with mutation p.Arg133Cys) than in control cells.[104] The relevance of PDGFR-
ß expression by Notch3 in CADASIL is not self evident, but it could explain why mutations in ligand binding and
nonligand-binding sites cause a similar disease.
Functional Pathogenesis
Whatever the pathogenetic mechanism causing the degeneration of VSMCs, is the key functional consequence of
impaired blood flow in small cerebral arteries to such an extent that lacunar infarcts ensue (Figure 1). The structural
alterations described above must be causally related to such CBF impairment. The destruction of VSMCs leads to
secondary fibrosis with marked thickening of the walls of small arteries as well as reduced compliance, and in the WM
arterioles also to stenosis of the lumen (Figures 7-9).[69] Consequently, CBF is decreased, as discussed in the above
section on Circulatory disturbances. The small penetrating WM arteries may become completely obliterated by the
fibrotic process, but most likely the final cause of the lacunar infarcts is thrombosis in the affected small arteries, this
view is supported by detection of fibrin degradation products in the plasma of CADASIL patients with recent strokes
[Ilveskero, Unpublished Observation]. The fibrosis and stenosis in the penetrating WM arterioles is significantly more
severe than in the cortical ones[69] and the lack of collaterals makes the WM more vulnerable. All these factors
explain the predominant localization of infarcts in WM and sparing of cortex.
On the other hand, the pathogenesis of common deep GM infarcts in basal ganglia (Figure 1) may have another,
possibly hemodynamic mechanism, since despite thickening of the walls such stenosis as in WM arterioles does not
occur in nucleus lentiformis arterioles (Figure 9).[70] In fact, hemodynamic perturbations due to rigidity of fibrosed
arterioles could also contribute to WM infarcts. Thus, not only could the severe and most probably late-occurring
stenosis cause WM infarcts (Figure 8), but also impaired vasodilation of the thick walled WM arterioles result in focal
ischemia. Increased blood flow into, and dilatation of, larger arteries necessitates flow-mediated vasodilatation of
'downstream' vessels to avoid 'steal' into high-flow vessels. A partial failure of vasodilatation in WM resistance
arterioles with a consequent decrease of blood flow might occur early in CADASIL.[61] The dilatation of the fibrosed
vessels is understandably decreased, which has also been verified as the lesser vasodilatory effect of acetazolamide.[58]
Furthermore, this phenomenon of flow-mediated vasodilatation is normally greater in the cerebral vasculature than in
other vascular beds, increasing the risk of 'steal' of blood flow from one vascular territory to another.[120] The
increased cortical and reduced WM blood flow in PET studies of young CADASIL patients could reflect such a 'steal'.
[57] And the lack of collaterals makes the subcortical area vulnerable to the 'steal' effect, similar to stenosis/occlusion.
Animal Models
16. Two approaches to develop transgenic mouse models of CADASIL have been reported. The French CADASIL team
produced transgenic mice, in which SM22a promoter drives humanNOTCH3 carrying p.Arg90>Cys substitution due
to c.268C>T mutation.[121] The findings in these experiments were, however, not compared with transgenic mice
overexpressing wild-type human Notch3. By the age of 17-20 months the mice overexpressing the mutant human
Notch3 developed in both cerebral and peripheral arteries similar vascular changes similar to CADASIL patients.
Accumulation of N3ECD in arterial walls was verified by immunohistochemistry. Electron microscopy disclosed
degeneration of VSMCs and deposition of small GOMs. VSMCs appeared to lose their normal anchorage to adjacent
extracellular matrix before the above mentioned deposits appeared. Despite these alterations, no parenchymal damage
was seen in the brains of the transgenic mice. In functional testing, the cerebovascular reactivity was found to be
compromised in these animals: CBF autoregulation was shifted towards higher blood pressures.[122] Furthermore,
the flow-induced dilatation was reduced and the pressure-induced myogenic tone was increased, which had occurred
at the age of 10 months prior to the abovementioned structural changes, indicating early vascular dysfunction.[62]
These results are in concordance with vascular dysfunction in CADASIL patients, in whom vasoreactivity to
acetazolamide and carbon dioxide is impaired,[58,123] as is flow-mediated vasodilatation in upper extremity
resistance arteries.[61] Furthermore, retinal arteries in young CADASIL patients are constricted as in hypertension.
[124] This mouse model was also used to show that the arterial defects of NOTCH3 -/- -knockout mice can be similarly
rescued by expression at comparable and physiological levels of both the wild-type human Notch3 and the mutant
p.Arg90> Cys human Notch3 (see above section, Molecular pathogenesis).[61]
In another study, a mouse knock-in model for one of the most prevalent human CADASIL mutations, p.Arg141>Cys,
was generated by making the corresponding alteration p.Arg142>Cys in mouse Notch3.[125] These mice, however, did
not develop a CADASIL-like phenotype. The mutated mouse Notch3 receptor was normally processed, N3ECD was
not accumulated, brain MRI was normal and no abnormal behavior or brain pathology was detected. This failure was
suggested to be at least in part due to species difference or the propensity of different mutations to produce a
phenotype in mouse, which might not be an ideal experimental animal in which to study late-onset diseases such as
CADASIL.[125]
Diagnosis & Differential Diagnosis in CADASIL
Diagnosis
A patient suffering from a cerebrovascular accident at a young age is usually examined by MRI. In CADASIL, the
MRI findings (Figures 1A-1D) are characteristic and almost specifically diagnostic (see previous page, Imaging). The
yield of positive gene analysis for CADASIL was 11% among patients below 50 years of age who had lacunar infarcts
and leukoaraiosis. Thus, it is worthwhile to perform genetic testing in such a population of patients.[10] Migraine with
aura alone often does not usually motivate to perform MRI, since migraine/headache is so common. Despite the low
probability, CADASIL should be considered, especially in late-onset migraine, if the aura is exceptionally severe or if
it begins or is aggravated during late pregnancy or puerperium.[21] Similar symptoms in relatives favor the possibility
of CADASIL, even though migraine as such may also be familial.[126]
Positive clinical and MRI findings necessitate either gene testing or electron microscopic/immunohistochemical
examination of a skin biopsy. Molecular genetic identification of a pathogenic NOTCH3 mutation gives the definite
diagnosis. The great number (>170) of different mutations makes the search for less common mutations relatively
cumbersome, even though analyses for the entire pathogenic regions of NOTCH3 gene begin to be available. The most
efficient strategy to search for the NOTCH3 mutations depends on the patient's family history and the mutational
background in the population of which the suspected patient is a member of. In families with a known mutation, one
should of course test directly for that mutation. In populations with known founder or major mutations, the analyses
should be directed to those mutations, restriction analysis being usually the most practical method.[127] In
populations with no known founder or other prevalent mutations, the mutational hot-spot regions - exons 3, 4, 5 and 8,
of the NOTCH3 gene - should be analyzed first and approximately 80% coverage exons 2, 6, 11 and 18 should be
included.
Owing to the problems mentioned above in the determination of the NOTCH3 mutation, a rapid and reliable
screening test has been called for.[128] The EM analysis for GOM (Figures 3 & 4) seems to provide such a test:[2] it is
easy to perform and the presence of GOM in the arterial walls appears to be 100% specific. Besides, we have detected
GOM in representative skin biopsies from all CADASIL patients with an identified NOTCH3 mutation, in other
words, the sensitivity also appears to be 100%. Thus, the detection of GOM seems to allow definite diagnosis of
CADASIL.[2] Since the arteriopathy is generalized, GOM can be detected in many different intra vitam tissue
17. biopsies. Most commonly, the biopsy is taken from skin but other neuropathological biopsies, for example, from
muscle or peripheral nerve, can also be used.[73,129] Some caution is, however, needed since the biopsy might not
have been deep enough (small arteries located in deep dermis or upper subcutis are optimal), in which cases the biopsy
needs to be repeated. Besides, true GOM needs to be distinguished from the nonspecific granular debris present
between degenerative VSMCs in some other diseases.[2]
Immunohistochemical demonstration of accumulated N3ECD provides another morphological diagnostic method,[68]
but an inherent caveat of this technique - false-positive immunoreactivity in other diseases - erodes its specificity.[43]
In addition, detection of small amounts of N3ECD at the early stages of the disease may be problematic (Figure 4B).
Thus, we highly recommend the electron microscopic analysis of GOM as the morphological diagnostic method.[2]
Differential Diagnosis
All CADASIL cases diagnosed so far have been familial and, thus, the presence of affected relatives lends support for
CADASIL. In familial hemiplegic migraine (FHM), migraine is associated with stroke-like symptoms, but the FHM
patients usually recover better from the attacks. Genetic tests for the defective genes (e.g., for CACNL1A4 in one type
of FHM) or EM analysis should allow correct diagnosis. Stroke may also associate with 'independent' migraine, and
migraine has been traditionally included among risk factors for stroke, although this may be true only for young
women.[130]
Recurrent embolizations, such as in cardiac arrhythmias or coagulation disturbances, may cause multiple lacunar
infarcts and they should be excluded by adequate examinations. WM infarcts are also a feature of subcortical
arteriolosclerotic encephalopathy (SAE; Binswanger's disease). Hypertension is commonly associated with SAE,
whereas CADASIL patients are most often normotensive, but risk factors of stroke, such as hypertension and
hypercholesterolemia, also occur in CADASIL patients.[25,43,51] Finally, strokes in young persons may be caused by
a mitochondrial encephalopathy, especially mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes
(MELAS) syndrome, but in these diseases infarcts are usually cortical and located in posterior parts of the brain.[131]
Interestingly, the frequency of mutations in mitochondrial DNA appears to be higher in CADASIL patients than in the
general population.[132]
Therapeutic Possibilities
The slow and unpredictable progression of CADASIL makes evaluation of therapeutic effects very difficult. At
present, only symptomatic therapy is available. Acutely, acetazolamide may be of help to CADASIL patients with
excruciating migraine,[133] whereas ergotamines and triptans should not be used in the treatment of the migraneous
headache, since they may cause vasospasms that may further impair the already compromised CBF. Since the
vascular pathology has been thought to give rise to local thromboses, anticoagulants or antiaggregants have been tried
without definite positive effects. In a few patients, these medications may have caused fatal parenchymal brain
hemorrhages. Since blood flow is impaired in the diseased arterioles due to progressive stenosis and rigidity, increased
blood viscosity, for example, due to polycythemia or dehydration, appears to be harmful and should be avoided [Own
Unpublished Observations]. For the same reason, medications causing cerebral hypoperfusion, such as tricyclic
antidepresants, neuroleptics and hypotensive drugs, should be administered with caution. Refraining from smoking is
recommended since smoking can increase the risk for stroke.[15]
Statins reduce the risk of stroke, especially in patients with coronary artery disease.[134] The role of statins is still
unknown in CADASIL,[134] but one half of the patients had hypercholesterolemia and therefore treatment with
statins is indicated.
Cognitive decline begins before ischemic attacks. Cholinergic deficits have been found in CADASIL patients in late
middle age (>45-50 years)[136-138] and, therefore, cholinesterase inhibitors may alleviate cognitive decline. In a
placebo-controlled study with donepezil, executive functions were moderately improved, but the clinical relevance of
this treatment is still unknown.[139]
Future Perspective
The pathogenesis of CADASIL is still unsettled. Most CADASIL mutations do not halt canonical Notch3 signaling.
Thus, the definite cause(s) of the degeneration of the VSMCs and the subsequent fibrosis of the arterioles appears to
be independent from the classical Notch3 signaling cascade and is perhaps caused by a still uncharacterized secondary
18. signaling pathway of the same receptor. Furthermore, the mechanism by which the blood flow in different parts of the
brain is impaired has not been definitively clarified, including the exact role of the endothelial malfunction. Finally,
none of the presently tested medications appears to offer effective therapeutic intervention.
Thus, new approaches should focus on the characterization of the still vaguely described alternative receptor targets
and on the possible prevention of a dominant negative/toxic effect of Notch3 (e.g., the accumulation of mutated
N3ECD on the VSMCs) or compensation for somehow defective signaling. Even though VSMCs of the cerebral
arterioles are beyond the blood-brain barrier, their close proximity to the blood flow should nonetheless allow the
future drug(s) to reach their target with relative ease.
References
1. Joutel A, Corpechot C, Ducros A et al. : Notch3 mutations in CADASIL, a hereditary late-onset condition
causing stroke and dementia. Nature 383, 707-710 (1996).
2. Tikka S, Mykkänen K, Ruchoux M-M et al. : Congruence between NOTCH3 mutations and GOM in 131
CADASIL patients. (2008) (In Press).
3. van Bogaert L: Encephalopathie sous-corticale progressive (Binswanger) a evolution rapide chez deuz soeurs.
Med. Hellen 24, 961-972 (1955).
4. Sourander P, Wålinder J: Hereditary multi-infarct dementia. Morphological and clinical studies of a new
disease. Acta Neuropathol. 39, 247-254 (1977).
5. Low WC, Junna M, Börjesson-Hanson A et al. : Hereditary multi-infarct dementia of the Swedish type is a novel
disorder different from NOTCH 3 causing CADASIL. Brain 130, 357-367 (2007).
6. Tournier-Lasserve E, Joutel A, Melki J et al. : Cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy maps to chromosome 19q12. Nat. Genet. 3, 256-259 (1993).
7. Joutel A, Vahedi K, Corpechot C et al. : Strong clustering and stereotyped nature of Notch3 mutations in
CADASIL patients. Lancet 350, 1511-1515 (1997).
8. Markus HS, Martin RJ, Simpson MA et al. : Diagnostic strategies in CADASIL. Neurology 59, 1134-1138 (2002).
9. Razvi SS, Davidson R, Bone I, Muir KW: The prevalence of cerebral autosomal dominant arteriopathy with
subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J. Neurol. Neurosurg.
Psychiatry 76, 739-741 (2005).
10. Dong Y, Hassan A, Zhang Z, Huber D, Dalageorgou C, Markus HS: Yield of screening for CADASIL mutations
in lacunar stroke and leukoaraiosis. Stroke 34, 203-205 (2003).
11. Markus HS, Martin RJ, Simpson MA et al. : Diagnostic strategies in CADASIL. Neurology 59, 1134-1138 (2002).
12. Chabriat H, Vahedi K, Iba-Zizen MT et al. : Clinical spectrum of CADASIL: a study of 7 families. Cerebral
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 346, 934-939
(1995).
13. Dichgans M, Mayer M, Uttner I et al. : The phenotypic spectrum of CADASIL: Clinical findings in 102 cases.
Ann. Neurol. 44, 731-739 (1998).
14. Kalimo H and Kalaria RN: Hereditary forms of vascular dementias. In: Pathology and Genetics:
Cerebrovascular Diseases . Kalimo H (Ed). Chapter 41. ISN Neuropath Press, Basel, 324-334 (2005).
15. Mykkänen K, Junna M, Amberla K et al. : Different clinical phenotypes in monozygotic CADASIL twins with a
novel NOTCH3 mutation. (2008) (In Press).
19. 16. Singhal S, Bevan S, Barrick T, Rich P, Markus HS: The influence of genetic and cardiovascular risk factors on
the CADASIL phenotype. Brain 127, 2031-2038 (2004).
17. Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M: Long-term prognosis and causes of death in CADASIL:
a retrospective study in 411 patients. Brain 127, 2533-2539 (2004).
18. Arboleda-Velasquez JF, Lopera F, Lopez E et al. : C455R notch3 mutation in a Colombian CADASIL kindred
with early onset of stroke. Neurology 59, 277-279 (2002).
19. Vahedi K, Chabriat H, Levy C, Joutel A, Tournier-Lasserve E, Bousser MG: Migraine with aura and brain
magnetic resonance imaging abnormalities in patients with CADASIL. Arch. Neurol. 61, 1237-1240 (2004).
20. Ophoff RA, Terwindt GM, Vergouwe MN, Frants RR, Ferrari MD: Wolff Award: Involvement of a Ca2+
channel gene in familial hemiplegic migraine and migraine with and without aura. Headache 37, 479-485 (1997).
21. Roine S, Pöyhönen M, Timonen S et al. : Neurologic symptoms are common during gestation and puerperium in
CADASIL. Neurology 64, 1441-1443 (2005).
22. Choi EJ, Choi CG, Kim JS: Medium to large cerebral artery involvement in CADASIL. Neurology 65, 1322-
1324 (2005).
23. Miao Q, Kalimo H, Bogdanovic N, Kostulas K, Börjesson-Hanson A, Viitanen M: Long penetrating cerebral
arterioles are early affected in CADASIL. Neuropathol. Appl. Neurobiol. 32, 455-458 (2006).
24. Mellies JK, Baumer T, Muller JA et al. : SPECT study of a German CADASIL family. A phenotype with
migraine and progressive dementia only. Neurology 50, 1715-1721 (1998).
25. Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP: The natural history of CADASIL: a pooled
analysis of previously published cases. Stroke 30, 1230-1233 (1999).
26. Choi JC, Kang SY, Kang JH, Park JK: Intracerebral hemorrhages in CADASIL. Neurology 66, 1511-1516
(2006).
27. Viswanathan A, Guichard JP, Gschwendtner A et al. : Blood pressure and haemoglobin A1c are associated with
microhaemorrhage in CADASIL: a two-centre cohort study. Brain 129, 2375-2383 (2006).
28. Kalimo H, Ruchoux MM, Viitanen M, Kalaria RN: CADASIL: a common form of hereditary arteriopathy
causing brain infarcts and dementia. Brain Pathol. 12, 371-384 (2002).
29. Amberla K, Waljas M, Tuominen S et al. : Insidious cognitive decline in CADASIL. Stroke 35, 1598-1602 (2004).
30. Peters N, Opherk C, Danek A, Ballard C, Herzog J, Dichgans M: The pattern of cognitive performance in
CADASIL: a monogenic condition leading to subcortical ischemic vascular dementia. Am. J. Psychiatry 162,
2078-2085 (2005).
31. Taillia H, Chabriat H, Kuetz A et al. : Cognitive alterations in non-demented CADASIL patients. Cerebrovasc.
Dis. 8, 97-101 (1998).
32. Trojano L, Ragno M, Manca A, Caruso G: A kindred affected by cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy (CADASIL): a 2-year neuropsychological follow-up. J.
Neurol. 245, 217-222 (1998).
33. Liem MK, van der Grond J, Haan J et al. : Lacunar infarcts are the main correlate with cognitive dysfunction in
CADASIL. Stroke 38, 923-928 (2007).
34. Viswanathan A, Gschwendtner A, Guichard JP et al. : Lesions are independently associated with disability and
cognitive impairment in CADASIL. Neurology 69, 172-179 (2007).
20. 35. Verin M, Rolland Y, Landgraf F, Chabriat H et al. : New phenotype of the cerebral autosomal dominat
arteriopathy mapped to chromosome 19: migraine as the prominent clinical feature. J. Neurol. Neurosurg.
Psych. 59, 579-585 (1995).
36. Lågas PA, Juvonen V: Schizophrenia in a patient with cerebral autosomally dominant arteriopathy with
subcortical infarcts and leucoencephalopathy (CADASIL disease). Nord. J. Psychiatry 55, 41-42 (2001).
37. Chabriat H, Bousser MG: Neuropsychiatric manifestations in CADASIL. Dialogues. Clin. Neurosci. 9, 199-208
(2007).
38. Valenti R, Poggesi A, Pescini F, Inzitari D, Pantoni L: Psychiatric disturbances in CADASIL: a brief review.
Acta Neurol. Scand. DOI: 10.1111/j.1600-0404.2008.01015.x (2008) (Epub ahead of print).
39. Haan J, Lesnik Oberstein SA, Ferrari MD: Epilepsy in cerebral autosomal dominant arteriopathy with
subcortical infarcts and leucoencephalopathy. Cerebrovasc. Dis. 24, 316-317 (2007).
40. Valko PO, Siccoli MM, Schiller A et al. : Nonconvulsive status epileptics causing focal neurological deficits in
CADASIL. J. Neurol. Neurosurg. Psychiatry 78, 1287-1289 (2007).
41. Schon F, Martin RJ, Prevett M et al. : 'CADASIL coma': an underdiagnosed acute encephalopathy. J. Neurol.
Neurosurg. Psychiatry 74, 249-252 (2003)
42. Sicurelli F, Dotti MT, De Stefano N et al. : Peripheral neuropathy in CADASIL. J. Neurol. 252, 1206-1209
(2005).
43. Lesnik Oberstein SA, Jukema JW, Van Duinen SG et al. : Myocardial infarction in cerebral autosomal
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Medicine (Baltimore) 82,
251-256 (2003).
44. Cumurciuc R, Henry P, Gobron C et al. : Electrocardiogram in cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy patients without any clinical evidence of coronary artery disease: a
case-control study. Stroke 37, 1100-1102 (2006).
45. Rufa A, Guideri F, Acampa M et al. : Cardiac autonomic nervous system and risk of arrhythmias in cerebral
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Stroke 38,
276-280 (2007).
46. Finsterer J: Neuromuscular implications in CADASIL. Cerebrovasc. Dis. 24, 401-404 (2007).
47. Davous P: CADASIL: a review with proposed diagnostic criteria. Eur. J. Neurol. 5, 219-233 (1998).
48. Lesnik Oberstein SA, van den Boom R, Middelkoop HA et al. : Incipient CADASIL. Arch. Neurol. 60, 707-712
(2003).
49. Peters N, Herzog J, Opherk C, Dichgans M: A two-year clinical follow-up study in 80 CADASIL subjects:
progression patterns and implications for clinical trials. Stroke 35, 1603-1608 (2004).
50. Junna M, Mykkänen K, Pescini F et al. : Genetic factors may modify the clinical course of CADASIL. (2008) (In
Press).
51. Chabriat H, Levy C, Taillia H et al. : Patterns of MRI lesions in CADASIL. Neurology 51, 452-457 (1998).
52. Chabriat H, Pappata S, Poupon C et al. : Clinical severity in CADASIL related to ultrastructural damage in
white matter: in vivo study with diffusion tensor MRI. Stroke 30, 2637-2643 (1999).
53. Lesnik Oberstein SA, van den Boom R, van Buchem MA et al. : The Dutch CADASIL Research Group: cerebral
microbleeds in CADASIL. Neurology 57, 1066-1070 (2001).
21. 54. Dichgans M, Holtmannspotter M, Herzog J, Peters N, Bergmann M, Yousry TA: Cerebral microbleeds in
CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke 33, 67-71 (2002).
55. Dichgans M, Petersen D: Angiographic complications in CADASIL. Lancet 349, 776-777 (1997).
56. Chabriat H, Bousser M-G, Pappata S: Cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy: a positron emission tomography study in two affected family members. Stroke 26, 1729-
1730 (1995).
57. Tuominen S, Miao Q, Kurki T et al. : Positron emission tomography examination of cerebral blood flow and
glucose metabolism in young CADASIL patients. Stroke 35, 1063-1067 (2004).
58. Chabriat H, Pappata S, Ostergaard L et al. : Cerebral hemodynamics in CADASIL before and after
acetazolamide challenge assessed with MRI bolus tracking. Stroke 31, 1904-1912 (2000).
59. Bruening R, Dichgans M, Berchtenbreiter C et al. : Cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy: decrease in regional cerebral blood volume in hyperintense subcortical
lesions inversely correlates with disability and cognitive performance. Am. J. Neuroradiol. 22, 1268-1274 (2001).
60. Liebetrau M, Herzog J, Kloss CU, Hamann GF, Dichgans M: Prolonged cerebral transit time in CADASIL: a
transcranial ultrasound study. Stroke 33, 509-512 (2002).
61. Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L: Impaired endothelial function of forearm resistance
arteries in CADASIL patients. Stroke 38, 2692-2697 (2007).
62. Dubroca C, Lacombe P, Domenga V et al. : Impaired vascular mechanotransduction in a transgenic mouse
model of CADASIL arteriopathy. Stroke 36, 113-117 (2005).
63. Baudrimont M, Dubas F, Joutel A, Tournier-Lasserve E, Bousser MG : Autosomal dominant
leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke 24, 122-125 (1993).
64. Ruchoux MM, Guerouaou D, Vandenhaute B, Pruvo JP, Vermersch P, Leys D: Systemic vascular smooth
muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy. Acta Neuropathol. 89, 500-512 (1995).
65. Tuominen S, Juvonen V, Amberla K et al. : Phenotype of a homozygous CADASIL patient in comparison to 9
age-matched heterozygous patients with the same R133C Notch3 mutation. Stroke 32, 1767-1774 (2001).
66. Brulin P, Godfraind C, Leteurtre E, Ruchoux MM: Morphometric analysis of ultrastructural vascular changes
in CADASIL: analysis of 50 skin biopsy specimens and pathogenic implications. Acta Neuropathol. 104, 241-248
(2002).
67. Ishiko A, Shimizu A, Nagata E, Takahashi K, Tabira T, Suzuki N: Notch3 ectodomain is a major component of
granular osmiophilic material (GOM) in CADASIL. Acta Neuropathol. 112, 333-339 (2006).
68. Joutel A, Favrole P, Labauge P et al. : Skin biopsy immunostaining with a Notch3 monoclonal antibody for
CADASIL diagnosis. Lancet 358, 2049-2051 (2001).
69. Miao Q, Paloneva T, Tuominen S et al. : Fibrosis and stenosis of the long penetrating cerebral arteries: the cause
of the white matter pathology in cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy. Brain Pathol. 14, 358-364 (2004).
70. Miao Q, Paloneva T, Tuisku S et al. : Arterioles of the lenticular nucleus in CADASIL. Stroke 37, 2242-2247
(2006).
71. Arboleda-Velasquez JF, Zhou Z, Shin HK et al. : Linking Notch signaling to ischemic stroke. Proc. Natl Acad.
Sci. USA 105, 4856-4861 (2008).
22. 72. Ruchoux MM, Maurage CA: Endothelial changes in muscle and skin biopsies in patients with CADASIL.
Neuropathol. Appl. Neurobiol. 24, 60-65 (1998).
73. Armulik A, Abramsson A, Betsholtz C: Endothelial/pericyte interactions. Circ. Res. 97, 512-523 (2005).
74. Domenga V, Fardoux P, Lacombe P et al. : Notch3 is required for arterial identity and maturation of vascular
smooth muscle cells. Genes Dev. 18, 2730-2735 (2004).
75. Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M: Enhanced L-arginine-induced vasoreactivity
suggests endothelial dysfunction in CADASIL. J. Neurol. DOI: 10.1007/s00415-008- 0876-9(2008) (Epub ahead
of print).
76. Joutel A, Dodick DD, Parisi JE, Cecillon M, Tournier-Lasserve E, Bousser MG: De novo mutation in the
NOTCH3 gene causing CADASIL. Ann. Neurol. 47, 388-391 (2000).
77. Coto E, Menéndez M, Navarrro R, Garcia-Castro M, Alvarez V: A de novo Notch3 mutation causing CADASIL.
Eur. J. Neurol. 13, 628-631 (2006).
78. Kotorii S, Takahashi K, Kamimura K et al. : Mutations of the NOTCH3 gene in non-Caucasian patients with
suspected CADASIL syndrome. Dement. Geriatr. Cogn. Disord. 12, 185-193 (2001).
79. Santa Y, Uyama E, Chui DH et al. : Genetic, clinical and pathological studies of CADASIL in Japan: a partial
contribution of Notch3 mutations and implications of smooth muscle cell degeneration for the pathogenesis. J.
Neurol. Sci. 212, 79-84 (2003).
80. Fouillade C, Chabriat H, Riant F et al. : Activating NOTCH3 mutation in a patient with small-vessel-disease of
the brain. Hum. Mutat. 29, 452-461 (2008).
81. Artavanis-Tsakonas S, Rand MD, Lake RJ: Notch signaling: cell fate control and signal integration in
development. Science 284, 770-776 (1999).
82. Lasky JL, Wu H: Notch signaling, brain development, and human disease. Pediatr. Res. 57, 104-109 (2005).
83. Roca C, Adams RH: Regulation of vascular morphogenesis by Notch signaling. Genes Dev. 21, 2511-2524 (2007).
84. Hansson EM, Lendahl U, Chapman G: Notch signaling in development and disease. Semin. Cancer Biol. 14, 320-
328 (2004).
85. Lardelli M, Williams R, Lendahl U: Notch-related genes in animal development. Int. J. Dev. Biol. 39, 769-80
(1995).
86. Gridley T. Notch signaling in vascular development and physiology. Development 134, 2709-2718 (2007).
87. Gray GE, Mann RS, Mitsiadis E et al. : Human ligands of the Notch receptor. Am. J. Pathol. 154, 785-94 (1999).
88. Shimizu K, Chiba S, Saito T, Kumano K, Hirai H: Physical interaction of Delta1, Jagged1, and Jagged2 with
Notch1 and Notch3 receptors. Biochem. Biophys. Res. Commun. 276, 385-389 (2000).
89. Nichols JT, Miyamoto A, Olsen SL, D'Souza B, Yao C, Weinmaster G: DSL ligand endocytosis physically
dissociates Notch1 heterodimers before activating proteolysis can occur. J. Cell Biol. 176, 445-458 (2007).
90. Parks AL, Klueg KM, Stout JR, Muskavitch MA: Ligand endocytosis drives receptor dissociation and activation
in the Notch pathway. Development 127, 1373-1385 (2000).
91. Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S: Intracellular cleavage of Notch leads to a
heterodimeric receptor on the plasma membrane. Cell 90, 281-291 (1997).
23. 92. Brou C, Logeat F, Gupta N et al. : A novel proteolytic cleavage involved in Notch signaling: the role of the
disintegrin-metalloprotease TACE. Mol. Cell 5, 207-216 (2000).
93. Mumm JS, Schroeter EH, Saxena MT et al. : A ligand-induced extracellular cleavage regulates ?-secretase-like
proteolytic activation of Notch1. Mol. Cell 5, 197-206 (2000).
94. Chyung JH, Raper DM, Selkoe DJ: ?-secretase exists on the plasma membrane as an intact complex that accepts
substrates and effects intramembrane cleavage. J. Biol. Chem. 280, 4383-4392 (2005).
95. Joutel A, Andreux F, Gaulis S et al. : The ectodomain of the Notch3 receptor accumulates within the
cerebrovasculature of CADASIL patients. J. Clin. Invest. 105, 597-605 (2000).
96. Prakash N, Hansson E, Betsholtz C, Mitsiadis T, Lendahl U: Mouse Notch 3 expression in the pre- and postnatal
brain: relationship to the stroke and dementia syndrome CADASIL. Exp. Cell Res. 278, 31-44 (2002).
97. Wang W, Struhl G: Drosophila epsin mediates a select endocytic pathway that DSL ligands must enter to
activate Notch. Development 131, 5367-5380 (2004).
98. Wang W, Struhl G: Distinct roles for mind bomb, neuralized and epsin in mediating DSL endocytosis and
signaling in Drosophila . Development 132, 2883-2894 (2005).
99. Dichgans M: Monogenic causes of ischemic stroke. In: Stroke Genetics. H Markus (Ed.). Oxford University
Press, NY, USA 127-163 (2003).
100. Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E: Pathogenic mutations associated with cerebral
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1
binding and Notch3 activity via the RBP/JK signaling pathway. Am. J. Hum. Genet. 74, 338-347 (2004).
101. Peters N, Opherk C, Zacherle S, Capell A, Gempel P, Dichgans M: CADASIL-associated Notch3 mutations have
differential effects both on ligand binding and ligand-induced Notch3 receptor signaling through RBP-Jk. Exp.
Cell Res. 299, 454-464 (2004).
102. Krebs LT, Xue Y, Norton CR et al. : Characterization of Notch3-deficient mice: normal embryonic development
and absence of genetic interactions with Notch 1 mutation. Genesis 37, 139-143 (2003).
103. Monet M, Domenga V, Lemaire B et al. : The archetypal R90C CADASIL-NOTCH3 mutation retains NOTCH3
function in vivo . Hum. Mol. Genet. 16, 982-992 (2007).
104. Jin S, Hansson EM, Tikka S et al. : Notch signaling regulates platelet-derived growth factor receptor-ß
expression in vascular smooth muscle cells. Circ. Res. 102, 1483-1491 (2008).
105. Hu QD, Ang BT, Karsak M et al. : F3/contactin acts as a functional ligand for Notch during oligodendrocyte
maturation. Cell 115, 163-175 (2003).
106. Martinez Arias A, Zecchini V, Brennan K et al. : CSL-independent Notch signalling: a checkpoint in cell fate
decisions during development? Curr. Opin. Genet. Dev. 12, 524-533 (2002).
107. Arboleda-Velasquez J, Rampal R, Fung E et al. : CADASIL mutations impair Notch3 glycosylation by Fringe.
Hum. Mol. Genet. 14, 1631-1649 (2005).
108. Sayeed A, Ng DT: Search and destroy: ER quality control and ER-associated protein degradation. Crit. Rev.
Biochem. Mol. Biol. 40, 75-91 (2005).
109. Karlström H, Beatus P, Dennaeus K, Chapman G, Lendahl U, Lundqvist J: A CADASIL mutated receptor
exhibits impaired intracellular trafficking and maturation but normal ligand-induced signaling. Proc. Natl
Acad. Sci. USA 99, 17119-17124 (2002).
110. Ihalainen S, Soliymani R, Iivanainen E et al. : Proteome analysis of cultivated vascular smooth muscle cells from
24. a CADASIL patient. Mol. Med. 13, 305-314 (2007).
111. Spinner NB: CADASIL: Notch signaling defect or protein accumulation problem? J. Clin. Invest. 105, 561-562
(2000).
112. Wang W, Prince CZ, Mou Y, Pollman MJ: Notch3 signaling in vascular mooth muscle cells induces c-FLIP
expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. J. Biol. Chem. 277, 21723-
21729 (2002).
113. Wang W, Prince CZ, Hu X, Pollman MJ: HRT1 modulates vascular smooth muscle cell proliferation and
apoptosis. Biochem. Biophys. Res. Commun. 308, 596-601 (2003).
114. Sweeney C, Morrow D, Birney YA et al. : Notch 1 and 3 receptor signaling modulates vascular smooth muscle
cell growth, apoptosis, and migration via a CBF-1/RBP-Jk dependent pathway. FASEB J. 18, 1421-1423 (2004).
115. Noseda M, Fu Y, Niessen K et al. : Smooth Muscle a-actin is a direct target of Notch/CSL. Circ. Res. 98, 1468-
1470 (2006).
116. Betsholtz C: Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth
Factor Rev. 15, 215-228 (2004).
117. Marmur JD, Poon M, Rossikhina M, Taubman MB: Induction of PDGF-responsive genes in vascular smooth
muscle. Implications for the early response to vessel injury. Circulation 86, 53-60 (1992).
118. Campos AH, Wang W, Pollman MJ, Gibbons GH: Determinants of Notch-3 receptor expression and signaling in
vascular smooth muscle cells: implications in cell-cycle regulation. Circ. Res. 91, 999-1006 (2002).
119. Wang W, Campos AH, Prince CZ, Mou Y, Pollman MJ: Coordinate Notch3-hairy-related transcription factor
pathway regulation in response to arterial injury. Mediator role of platelet-derived growth factor and ERK. J.
Biol. Chem. 277, 23165-23171 (2002).
120. Heistad DD: What's new in the cerebral microcirculation? Landis award lecture. Microcirculation. 8, 365-375
(2001).
121. Ruchoux MM, Domenga V, Brulin P et al. : Transgenic mice expressing mutant Notch3 develop vascular
alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy. Am. J. Pathol. 162, 329-342 (2003).
122. Lacombe P, Oligo C, Domenga V, Tournier-Lasserve E, Joutel A: Impaired Cerebral vasoreactivity in a
transgenic mouse model of cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy arteriopathy. Stroke 36, 1053-1058 (2005).
123. Pfefferkorn T, von Stuckrad-Barre S, Herzog J, Gasser T, Hamann GF, Dichgans M: Reduced cerebrovascular
CO2reactivity in CADASIL: a transcranial Doppler sonography study. Stroke 32, 17-21 (2001).
124. Roine S, Harju M, Kivelä T et al. : Ophthalmologic findings in cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL). A cross-sectional study. Ophthalmology 113, 1411-
1417 (2006).
125. Lundkvist J, Zhu S, Hansson E et al. : Mice carrying a R142C Notch 3 knock-in mutation do not develop a
CADASIL-like phenotype. Genesis 41, 13-22 (2004).
126. Wessman M, Kallela M, Kaunisto MA et al. : A susceptibility locus for migraine with aura, on chromosome
4q24. Am. J. Hum. Genet. 70, 652-662 (2002).
127. Mykkänen K, Savontaus ML, Juvonen V et al. : Detection of the founder effect in Finnish CADASIL families.
Eur. J. Hum. Genet. 12, 813-819 (2004).
25. 128. Inzitari D, Sarti C: Screening for CADASIL mutations. Stroke 34, 205-206 (2003).
129. Schröder JM, Sellhaus B, Jorg J: Identification of the characteristic vascular changes in a sural biopsy of a case
with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
Acta Neuropathol. 89, 116-121 (1995).
130. Tzourio C, Tehindrazanarivelo A, Iglésias S et al. : Case-control study of migraine and risk of ischaemic stroke
in young women. Br. Med. J. 310, 830-833 (1995).
131. Majamaa K, Turkka J, Kärppä M, Winqvist S, Hassinen IE: The common MELAS mutation A3243G in
mitochondrial DNA among young patients with an occipital brain infarct. Neurology 49, 1331-1334 (1997).
132. Annunen-Rasila J, Finnilä S, Mykkänen K et al. : Mitochondrial DNA sequence variation and mutation rate in
patients with CADASIL. Neurogenetics 7, 185-194 (2006); erratum in: Neurogenetics 7, 281 (2006).
133. Forteza AM, Brozman B, Rabinstein AA, Romano JG, Bradley WG: Acetazolamide for the treatment of
migraine with aura in CADASIL. Neurology 57, 2144-2145 (2001).
134. Nassief A, Marsh JD: Statin therapy for stroke prevention. Stroke 39, 1042-1048 (2008).
135. Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M: Effects of short term atorvastatin treatment on
cerebral hemodynamics in CADASIL. J. Neurol. Sci 260, 100-105 (2007).
136. Mesulam M, Siddique T, Cohen B : Cholinergic denervation in a pure multi-infarct state: observations on
CADASIL. Neurology 60, 1183-1185 (2003).
137. Keverne JS, Low WC, Ziabreva I, Court JA, Oakley AE, Kalaria RN: Cholinergic neuronal deficits in
CADASIL. Stroke 38, 188-191 (2007).
138. Manganelli F, Ragno M, Cacchiò G et al. : Motor cortex cholinergic dysfunction in CADASIL: a transcranial
magnetic demonstration. Clin. Neurophysiol. 119, 351-355 (2008).
139. Dichgans M, Markus HS, Salloway S et al. : Donepezil in patients with subcortical vascular cognitive
impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 7, 310-318 (2008).
Addendum
A new version of topic of the month publication is uploaded in my web site every month (it remains for a month and is
changed with the monthly update of the neurology bulletin at:.http://neurology.yassermetwally.com)
To download the current version of topic of the month publication follow the link
quot;http://neurology.yassermetwally.com/topic.zipquot;
You can also download the current version of topic of the month publication from within the publication or go to my
web site at: quot;http://yassermetwally.comquot; to download it.
At the end of each year, all the publications are compiled on a single CD-ROM, please author to know more details.
Screen resolution is better set at 1024*768 pixel screen area for optimum display
For an archive of the previously published topics in downloadable PDF format go to http://yassermetwally.net, then
under pages in the right panel, scroll down and click on the text entry quot;topic of the monthquot;
In order to view a list of the previously published topics in downloadable PDF format, follow the link:
http://wordpress.com/tag/neurological-topic-of-the-month/
The author: Professor Yasser Metwally, professor of neurology, Ain Shams university, Cairo, Egypt
www.yassermetwally.com